



Non-alcoholic fatty liver disease (NAFLD) is a 
condition with excessive fat accumulation in 
hepatocytes [1]. NAFLD is often classified as 
primary and secondary according to the underly-
ing etiology [2]. Primary NAFLD generally refers 
to fatty liver associated with features of the 
metabolic syndrome [3], and in fact, NAFLD may 
be considered as hepatic manifestation of the 
metabolic syndrome [4]. 
 
Recent studies on the development and pro-
gression of NAFLD emphasize the pathophysi-
ological role of cytokines and chemokines be-
sides that of insulin resistance, oxidative stress 
and lipid peroxidation [5]. Chemokines repre-
sent a large superfamily of proteins that pos-
sess diverse biologic activities [6]. Regulated 
upon Activation, Normal T-cell Expressed, and 
Secreted (RANTES, also known as CCL5) is a CC 
beta-chemokine with strong chemoattractant 
activity for T lymphocytes and monocytes [7]. It 
has been implicated in the pathogenesis of nu-
merous diseases including cancer [8], neuro-
logical disorders [9], asthma [10], autoimmune 
diseases such as rheumatoid arthritis [11] and 
renal diseases [12].  
 
Increased (hepatic) RANTES expression has 
been reported in patients with chronic viral 
hepatitis [13,14], and a comprehensive study 
by Seki and colleagues [15] has shown that 
(increased expression of) RANTES promotes 
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hepatic inflammation and fibrosis in the bile 
duct ligation model and in a model of chronic 
toxic liver injury by application of tetracarbon-
chloride. Furthermore, it has been reported that 
obesity promotes chemokine expression in pa-
tients with chronic hepatitis C infection [16], 
and increased hepatic RANTES expression has 
been observed in a murine NASH-model [17] 
and in obese patients [18]. 
 
Based on the hypothesis that increased hepatic 
RANTES expression is an early event in NAFLD 
and a critical factor influencing its progression 
the aim of the present study was to analyze the 
effect of hepatocellular lipid accumulation on 
RANTES expression in the absence of significant 
hepatic inflammation. 
 
Materials and methods 
 
Primary human hepatocytes and in vitro model 
of hepatocellular lipid accumulation 
 
Isolation and culture of primary human hepato-
cytes (PHH) were performed as described [19]. 
Human liver tissue for cell isolation was ob-
tained according to the guidelines of the chari-
table state-controlled foundation HTCR with the 
patient's informed consent. Hepatocellular lipid 
accumulation was induced as described [20]. 
Briefly, a 10 mM palmitate/1% bovine serum 
albumin (BSA) stock solution was obtained by 
complexing the appropriate amount of palmitate 
to BSA. PHH were grown in DMEM supple-
mented with penicillin (400 U/ml), streptomycin 
(50 mg/ml), L-glutamine (300 mg/ml), 0.2% 
FCS and palmitate for 24h in different concen-
trations as indicated. FFA-free-BSA-treated cells 
served as controls.  
 
Intracellular triglyceride assay 
 
Total triglycerides were extracted using the 
method of Bligh and Dyer with slight modifica-
tions [21,22] and quantified by the triglyceride 
determination kit (GPO) (Sigma, Deisenhofen, 
Germany) as described [20]. 
 
Murine model of hepatic steatosis  
 
Male BALB/c mice were purchased from 
Charles River Laboratories (Sulzfeld, Germany) 
at 6 weeks of age and housed under standard 
conditions. After 1 week of acclimatization mice 
were divided into two groups (n=6 each) and 
fed either with control diet or a high fat diet 
(HFD) containing 30% lard. All chows were pre-
pared by Ssniff (Soest, Germany). After 12 
weeks feeding animals were sacrificed. Liver 
tissue and epididymal fat were immediately 
snap-frozen and stored at -80°C for subsequent 
analysis.  
 
Human serum samples of patients with ultra-
sound-diagnosed fatty liver and control patients 
 
Serum samples were obtained from randomly 
selected patients recruited from the referrals of 
the ultrasound (US) centre at our clinic from 
January 2008 to January 2009. According to the 
results of a standardized ultrasound examina-
tion participants were divided into 2 groups – a 
control group with normal US liver appearance 
and a group of patients with US-diagnosed fatty 
liver. The following exclusion criteria were ap-
plied: history of malignancy of any kind, chronic 
hepatobiliary diseases, use of medication 
known to affect hepatic steatosis (e.g. glucocor-
ticoids, anti-estrogens), inflammatory bowel 
disease, human immunodeficiency virus infec-
tion, drug or alcohol abuse (more than 20 g/
day), familial hyperlipidemia, and acute medical 
emergencies. Further, patients with clinical or 
laboratory signs of systemic inflammation were 
excluded to omit possible confounding effect on 
serum RANTES. 
 
After collection serum samples were immedi-
ately snap frozen and stored at -80°C. Informed 
consent was obtained from all patients and the 
study was approved by the local Ethics Commit-
tee. 
 
RANTES expression analysis 
 
Isolation of total cellular RNA from cultured cells 
and tissues and reverse transcription were per-
formed as described [23]. Quantitative real time
-PCR was performed with specific sets of prim-
ers applying LightCycler technology (Roche, 
Mannheim, Germany) as described [24] and 
specific human and mouse RANTES Primer as-
says (Qiagen, Hilden, Germany). 
 
Analysis of RANTES serum levels 
 
RANTES in human sera was assessed by sand-
wich enzyme-linked immunosorbent assay 
(ELISA) using the human CCL5 DuoSet ELISA 
development kit (R&D Systems Inc., MN, USA, 
catalog number DY278). 
RANTES in hepatic steatosis  
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Statistical analysis 
 
Statistical analysis was performed using SPSS 
version 15.0 (SPSS, Chicago, IL, USA) and 
GraphPad Prism Software (GraphPad Software, 
Inc., San Diego, USA). Results are expressed as 
means ± standard error (range). Comparisons 
between groups were made using one way 
analysis of variance (with Bonferroni correction 
for multiple comparisons). P-values <0.05 were 




Hepatocellular lipid accumulation induced 
RANTES expression in vitro 
 
Recently, we have described an in vitro model of 
hepatocellular lipid accumulation [20]. Incuba-
tion of primary human hepatocytes (PHH) with 
palmitic acid led to a dose dependent increase 
of hepatocellular free fatty acid and triglyceride 
levels [20]. Interestingly, this lipid accumulation 
led to a significant induction of RANTES mRNA 
expression in PHH (Figure 1). 
 
Increased hepatic RANTES expression in stea-
totic murine livers 
 
Next, we analyzed RANTES expression in livers 
of mice fed a high-fat diet (HFD) [25]. Feeding 
this diet led to significant hepatic lipid accumu-
lation (Figure 2A). In contrast mice in the HFD-
group had normal levels serum transaminases 
(Figure 2B) and revealed only slightly elevated 
TNF mRNA expression (Figure 2C).  
 
Activated hepatic stellate cells (HSC) are the 
cellular source of excessive extracellular matrix 
Figure 1. RANTES expression in an in vitro model of 
hepatocellular lipid accumulation. Primary human 
hepatocytes were incubated with 0.4 µM, 0.6 µM and 
0.8 µM palmitate (Palm.) for 24 h, which leads to a 
dose dependent intracellular lipid accumulation as 
shown before [20]. Subsequently, RNA was isolated, 
reverse transcribed and RANTES mRNA expression 
was analyzed by quantitative PCR. (*p<0.05 com-
pared to control (ctr.)). 
Figure 2. RANTES expres-
sion in the liver and in vis-
ceral fat in a murine model 
of NAFLD. Mice were fed a 
high fat diet leading to he-
patic steatosis. Mice receiv-
ing standard chow served 
as control (ctr.). (A) Assess-
ment of hepatic triglyceride 
content. (B) Serum GOT 
levels. Analysis of (C) he-
patic TNF, collagen I, α-
smooth muscle actin (α-
sma), and RANTES mRNA 
expression, and (D) expres-
sion of RANTES mRNA in 
visceral fat by quantitative 
PCR. (*p<0.05 compared to 
control). 
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deposition in chronic liver injury [26], and previ-
ous studies have shown increased RANTES ex-
pression in activated HSC [27]. However, nei-
ther expression of alpha-smooth muscle actin, a 
sensitive marker of HSC activation, nor collagen 
I expression was elevated in HFD-fed mice, indi-
cating that there was no relevant activation of 
HSC in the livers of these animals (Figure 2C). 
However and notably, RANTES expression was 
significantly increased in mice fed with the HFD 
(Figure 2C). 
 
It has been shown that visceral fat is a signifi-
cant source of proinflammatory cytokines in-
cluding RANTES [28,29]. Therefore, we also 
analyzed RANTES expression in visceral fat but 
found only minimally increased mRNA expres-
sion compared to control mice (Figure 2D). 
 
Increased RANTES serum levels in patients with 
non-alcoholic fatty liver  
 
Recently, we have described a cohort of pa-
tients with referral for sonographic examination 
of the abdomen and ultrasound-diagnosed 
NAFLD [30]. Analysis of serum levels of RANTES 
revealed slightly but significantly elevated 
RANTES levels in patients with ultrasound-
diagnosed NAFLD (n=45; mean: 85.9 ng/ml, 
SEM 3.7 ng/ml,) in comparison to the control 
group (n=61; mean: 60.1 ng/ml,  SEM 2.9 ng/




The chemokine RANTES has been shown to play 
a central role in the pathogenesis and progres-
sion of chronic liver disease, however, present 
information regarding its expression in nonalco-
holic fatty liver disease (NAFLD) is sparse [31]. 
 
RANTES has been shown to be expressed by 
hepatocytes and is up-regulated in response to 
inflammatory conditions [14;32-34]. Here, we 
reveal that lipid accumulation did also dose-
dependently induce RANTES expression in pri-
mary human hepatocytes in vitro. Thus, pure 
hepatocellular steatosis leads to increased he-
patic RANTES expression. In line with this, we 
observed that feeding a high-fat diet induced 
hepatic RANTES expression in the absence of 
significant hepatic inflammation or fibrosis. This 
finding further confirms steatotic hepatocytes 
but not infiltrating inflammatory cells or acti-
vated hepatic stellate cells as main cellular 
sources of elevated hepatic RANTES expression 
in high-fat diet fed mice. 
 
Nevertheless, it has to be considered that obe-
sity frequently leads to up-regulation of cyto-
kines as a part of a systemic state of low inflam-
mation not only in the liver but also in (visceral) 
adipose tissue, which is another important 
source of circulating cytokines including 
RANTES [29]. However, in our study, RANTES 
expression in visceral fat of mice, which were 
fed with a high-fat diet, was similar to the con-
trol group. This suggests that at least under 
these experimental conditions the fatty liver but 
not adipose tissue is the source of elevated 
(circulating) RANTES levels. 
 
Taken together with our in vitro data and the 
known pathophysiological role of RANTES in 
other chronic liver diseases, this indicates that 
steatosis-triggered RANTES production by hepa-
tocytes is an early event during the natural 
course of NAFLD and may be involved, along 
with other factors/cytokines, in the progression 
of fatty liver to significant inflammation, e.g. 
NASH.  
 
Interestingly, patients with US-diagnosed NAFLD 
had significantly elevated RANTES serum levels 
Figure 3. Serum RANTES levels in patients with 
NAFLD. Serum RANTES levels in patients with ultra-
sound (US) diagnosed fatty liver compared to a con-
trol (ctr.) group of patients with normal sonographic 
liver appearance. (*p<0.05 compared to control). 
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compared to the control group, although this 
increase was only moderate compared to the 
induction of RANTES mRNA expression in in 
vitro lipid loaded hepatocytes and murine fatty 
livers. However, although US examination can 
be adequately used to assess hepatic steatosis 
[35,36], it has to be considered that the reliable 
threshold is approximately 30% fat in the he-
patic tissue [37]. Thus, it is likely that a signifi-
cant number of patients in the control group 
also had hepatic steatosis below the US-
detection level. NAFLD is generally defined by 
lipid deposition greater than 5-10% of the liver 
weight [1], and our in vitro data indicate that 
even minimal hepatocellular lipid accumulation 
leads to increased RANTES levels. Conversely, 
despite the lack of histological examination in 
this hospital cohort of randomly selected pa-
tients, it can be estimated from epidemiological 
studies [38], that only a minority of cases had 
significant hepatic inflammation (e.g. criteria for 
NASH), which may have caused elevated 
RANTES levels. 
 
In summary, our study indicates that hepatic 
steatosis causes an up-regulation of hepatic 
RANTES expression. Noteworthy, increased ex-
pression of RANTES in response to hepatocellu-
lar lipid accumulation can occur in the absence 
of relevant hepatic inflammation. This finding 
further indicates that hepatic steatosis per se 
has pathophysiological relevance and should 
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